Fig. S5 from Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas

Gao, Xin; Kady, Nermin; Wang, Chenguang; Abdelrahman, Suhaib; Gann, Peter; Sverdlov, Maria; Wolfe, Ashley; Brown, Noah; Reneau, John; Robida, Aaron M.; Murga-Zamalloa, Carlos; Wilcox, Ryan A.

doi:10.1158/2767-9764.22545942.v1

sorry, we can't preview this file

crc-22-0336-s05.docx (103.14 kB)

Fig. S5 from Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas

journal contribution

posted on 2023-04-04, 02:00 authored by Xin Gao, Nermin Kady, Chenguang Wang, Suhaib Abdelrahman, Peter Gann, Maria Sverdlov, Ashley Wolfe, Noah Brown, John Reneau, Aaron M. Robida, Carlos Murga-Zamalloa, Ryan A. Wilcox

Macrophage depletion in MaFIA mice.

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

LAMs are a therapeutic vulnerability, as their depletion impairs T-cell lymphoma disease progression. Pacritinib, a dual CSF1R/JAK inhibitor, effectively impaired LAM viability and expansion, prolonged survival in preclinical T-cell lymphoma models, and is currently being investigated as a novel therapeutic approach in these lymphomas.

Usage metrics

Keywords

Hematological Cancers Lymphomas Small Molecule Agents Kinase inhibitors Tumor Microenvironment Immune cells and the microenvironment Progression, Invasion & Metastasis Tumor progression Immunology Tumor-associated macrophages

Licence

CC BY

sorry, we can't preview this file

Fig. S5 from Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports